International Journal of Peptide Research and Therapeutics

, Volume 15, Issue 3, pp 205–210

Quantitative Analysis of β-Amyloid Peptides Expressed in Human Cerebrospinal Fluid by an Improved Method of Antibody-Assisted Time-of-Flight Mass Spectrometry

Authors

    • Department of Brain Disease Pathogenesis Research, Translational Research Informatics CenterFoundation for Biomedical Research and Innovation
    • Faculty of Pharmaceutical SciencesHImeji-Dokkyo University
  • Reiko Matsumoto
    • Medical CorporationMidorikawa Clinic of Neurology
    • Department of PathologyKyoto University Graduate School of Medicine
  • Kei-ichi Kadoyama
    • Faculty of Pharmaceutical SciencesHImeji-Dokkyo University
  • Taka-aki Nishimoto
    • Faculty of Pharmaceutical SciencesHImeji-Dokkyo University
  • Shogo Matsuyama
    • Faculty of Pharmaceutical SciencesHImeji-Dokkyo University
  • Osamu Midorikawa
    • Kaken General Research Institute
    • Department of PathologyKyoto University Graduate School of Medicine
Article

DOI: 10.1007/s10989-009-9174-3

Cite this article as:
Matsumoto, A., Matsumoto, R., Kadoyama, K. et al. Int J Pept Res Ther (2009) 15: 205. doi:10.1007/s10989-009-9174-3

Abstract

Establishment of diagnostic measures for early stage Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is of crucial importance. Using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), antibody-assisted MS of cerebrospinal fluid (CSF) has enabled quantitative analysis of the ratio of β-amyloid (Aβ) peptides, Aβ1-42/Aβ1-40, which has a diagnostic value for AD/MCI. To apply the MS analysis to a far wider range of CSF samples, we have established a method to analyze Aβ peptides expressed in 100 μl CSF samples quantitatively. Pretreatment of CSF samples by limit-filtration to condense peptides, and modified washing procedure using urea as denaturant, Aβ peptides of interest can be assessed with higher sensitivity by five to tenfolds to the original method. This improvement enables quantitative analysis of Aβ species from a residual amount of CSF samples, which will be occasionally obtained in case of lumbar anesthesia prior to operation and spinal tap performed for routine diagnostic purposes. Prevalence of the new procedure as laboratory test, especially among the elderly consulting for neurological clinic, will enhance the number of subjects diagnosed at early stage of AD/MCI.

Keywords

Alzheimer’s diseaseMild cognitive impairmentDementiaβ-AmyloidCerebrospinal fluidMass spectrometryProteinChip™Bio-marker

Copyright information

© Springer Science+Business Media, LLC 2009